Vision - Conquer prostate cancer
Prostate cancer is the most commonly diagnosed cancer in men and is the second most common cause of male death from cancer. In 2016, approximately 180,890 men in the U.S. will be diagnosed with prostate cancer and an estimated 26,120 will die from it. In addition, there are major population disparities in prostate cancer incidence and mortality, with African American men experiencing 2.5 times greater risk of prostate cancer death compared to Caucasian men. The Prostate Cancer Research Program prioritizes research that will 1) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer, 2) develop strategies to prevent progression to lethal prostate cancer, 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer, and 4) develop strategies to optimize the physical and mental health of men with prostate cancer. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.
Dr. John Kurhanewicz
University of California, San Francisco
Hyperpolarized Molecular Imaging Biomarkers in a Novel Prostate Tissue Slice Culture Model
Last updated Thursday April 28 2016